Jeil Pharma Holdings Inc (KRX: 002620)
South Korea
· Delayed Price · Currency is KRW 8,230.00
-120.00 (-1.44%)
Nov 15, 2024, 3:30 PM KST
Jeil Pharma Holdings Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 774,611 | 794,714 | 787,256 | 756,633 | 755,330 | 725,458 | Upgrade
|
| Other Revenue | 8,945 | 9,329 | 5,708 | 5,935 | 6,667 | 6,347 | Upgrade
|
| Revenue | 783,556 | 804,043 | 792,965 | 762,568 | 761,997 | 731,805 | Upgrade
|
| Revenue Growth (YoY) | -0.94% | 1.40% | 3.99% | 0.07% | 4.13% | 412.70% | Upgrade
|
| Cost of Revenue | 577,282 | 589,459 | 612,482 | 582,061 | 570,757 | 549,304 | Upgrade
|
| Gross Profit | 206,274 | 214,584 | 180,483 | 180,507 | 191,239 | 182,501 | Upgrade
|
| Selling, General & Admin | 151,603 | 147,727 | 146,465 | 149,808 | 144,028 | 140,088 | Upgrade
|
| Research & Development | 46,145 | 46,038 | 41,566 | 39,673 | 24,731 | 22,452 | Upgrade
|
| Other Operating Expenses | 19,196 | - | - | - | - | 9,513 | Upgrade
|
| Operating Expenses | 216,747 | 193,664 | 188,031 | 189,482 | 169,236 | 173,371 | Upgrade
|
| Operating Income | -10,473 | 20,920 | -7,548 | -8,975 | 22,003 | 9,130 | Upgrade
|
| Interest Expense | -10,327 | -10,672 | -5,952 | -3,289 | -3,194 | -2,858 | Upgrade
|
| Interest & Investment Income | 2,102 | 4,119 | 508.95 | 256.81 | 179.62 | 336.73 | Upgrade
|
| Earnings From Equity Investments | - | - | - | 2,516 | 623.76 | -211.19 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,168 | -169.48 | 314.8 | 816.09 | -722.45 | 364.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -12,051 | -2,492 | 856.19 | -2,864 | 344.45 | 535.77 | Upgrade
|
| EBT Excluding Unusual Items | -29,581 | 11,706 | -11,820 | -11,539 | 19,235 | 7,298 | Upgrade
|
| Impairment of Goodwill | -28,604 | -28,604 | -78,335 | -17,014 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 2,578 | 2,923 | 7,127 | 20,876 | 16,146 | 8,019 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.52 | 0.53 | 23.98 | 1,930 | 6.69 | 2.73 | Upgrade
|
| Asset Writedown | -7.42 | -7.42 | -856.39 | -382 | -4,566 | -97,532 | Upgrade
|
| Pretax Income | -55,617 | -13,982 | -83,861 | -6,129 | 30,822 | -82,213 | Upgrade
|
| Income Tax Expense | 4,235 | -740.82 | -715.62 | 6,741 | 15,881 | 13,296 | Upgrade
|
| Earnings From Continuing Operations | -59,852 | -13,241 | -83,145 | -12,870 | 14,941 | -95,509 | Upgrade
|
| Net Income to Company | -59,852 | -13,241 | -83,145 | -12,870 | 14,941 | -95,509 | Upgrade
|
| Minority Interest in Earnings | 20,317 | -3,009 | 8,589 | 9,388 | -3,510 | 5,017 | Upgrade
|
| Net Income | -39,535 | -16,250 | -74,556 | -3,482 | 11,431 | -90,492 | Upgrade
|
| Net Income to Common | -39,535 | -16,250 | -74,556 | -3,482 | 11,431 | -90,492 | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | - | 195.86% | Upgrade
|
| EPS (Basic) | -2575.39 | -1058.54 | -4856.70 | -226.85 | 744.64 | -5894.82 | Upgrade
|
| EPS (Diluted) | -2575.85 | -1059.00 | -4857.00 | -227.00 | 744.64 | -5894.82 | Upgrade
|
| Free Cash Flow | -5,972 | -10,638 | -32,717 | -10,284 | -33,482 | -12,471 | Upgrade
|
| Free Cash Flow Per Share | -389.06 | -692.99 | -2131.27 | -669.95 | -2181.10 | -812.36 | Upgrade
|
| Dividend Per Share | 50.000 | 50.000 | 50.000 | 65.000 | 70.000 | 70.000 | Upgrade
|
| Dividend Growth | 0% | 0% | -23.08% | -7.14% | 0% | - | Upgrade
|
| Gross Margin | 26.33% | 26.69% | 22.76% | 23.67% | 25.10% | 24.94% | Upgrade
|
| Operating Margin | -1.34% | 2.60% | -0.95% | -1.18% | 2.89% | 1.25% | Upgrade
|
| Profit Margin | -5.05% | -2.02% | -9.40% | -0.46% | 1.50% | -12.37% | Upgrade
|
| Free Cash Flow Margin | -0.76% | -1.32% | -4.13% | -1.35% | -4.39% | -1.70% | Upgrade
|
| EBITDA | 2,867 | 33,476 | 3,357 | 8.31 | 30,654 | 16,526 | Upgrade
|
| EBITDA Margin | 0.37% | 4.16% | 0.42% | 0.00% | 4.02% | 2.26% | Upgrade
|
| D&A For EBITDA | 13,340 | 12,556 | 10,905 | 8,983 | 8,651 | 7,396 | Upgrade
|
| EBIT | -10,473 | 20,920 | -7,548 | -8,975 | 22,003 | 9,130 | Upgrade
|
| EBIT Margin | -1.34% | 2.60% | -0.95% | -1.18% | 2.89% | 1.25% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 51.52% | - | Upgrade
|
| Advertising Expenses | - | 5,929 | 6,228 | 8,742 | 10,675 | 6,981 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.